Related Experiment Videos
Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis
C J McKay1, F Curran, C Sharples
1Department of Surgery, Glasgow Royal Infirmary, UK.
Insights
Lexipafant, a platelet-activating factor antagonist, significantly reduced organ failure scores in patients with severe acute pancreatitis. This suggests its potential as an adjunctive therapy to improve outcomes in critical care settings.
Area of Science:
- Critical Care Medicine
- Pharmacology
Background:
- Severe acute pancreatitis frequently leads to organ system failure and early mortality.
- Current treatment for severe acute pancreatitis is primarily supportive, lacking specific therapeutic interventions.
Purpose of the Study:
- To evaluate the efficacy of lexipafant, a platelet-activating factor antagonist, in managing severe acute pancreatitis.
- To assess the impact of lexipafant on organ failure scores and systemic complications in patients with severe acute pancreatitis.
Main Methods:
- A randomized controlled trial involving 50 patients with predicted severe acute pancreatitis across 11 hospitals.
- Patients received either placebo or lexipafant (100 mg/day IV for up to 7 days).
- Organ failure scores were used to assess early systemic complications.
Main Results:
- The lexipafant treatment group showed a significantly greater reduction in organ failure scores compared to the placebo group (P = 0.003).
- Trends towards reduced mortality and fewer systemic complications were observed in the lexipafant group.
- Mean and median changes in organ failure score were -1.42 and -1 for lexipafant versus 0.17 and 0 for placebo.
Conclusions:
- Lexipafant demonstrates potential as an effective adjunctive therapy for severe acute pancreatitis.
- Early administration of lexipafant may help mitigate organ system failure and improve patient outcomes.
- Further research is warranted to confirm the benefits of lexipafant in severe acute pancreatitis management.
Background:
Many patients with severe acute pancreatitis develop organ system failure during the first few days of illness, and this accounts for the majority of early deaths. No specific therapy is available and treatment remains supportive.
Methods:
In a randomized controlled trial conducted in 11 hospitals in the West of Scotland, 50 patients with predicted severe acute pancreatitis were selected from 188 screened over a 14-month period. Patients received placebo or lexipafant, a potent platelet-activating factor antagonist, by continuous intravenous infusion at a dose of 100 mg/day for up to 7 days. Early systemic complications were assessed by the measurement of organ failure scores.
Results:
There was a significantly greater fall in organ failure score in the treatment group during the 7 days of study (mean and median changes in organ failure score were 0.17 and 0 in the placebo group versus -1.42 and -1 in the treatment group; P = 0.003, Wilcoxon rank sum test), associated with trends towards a reduction in mortality and a reduced incidence of systemic complications.
Conclusion:
These results suggest that lexipafant may be a useful adjunct to full supportive care in the early management of patients with severe acute pancreatitis.